Last updated on July 2018

cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China

Brief description of study

The purpose of this study is to evaluate the mutation pattern of epidermal growth factor receptor (EGFR) and other TKI targeted gene during TKI treatment of advanced NSCLC patient with liquid biopsy.

Detailed Study Description

In the study, 200 advanced NSCLC patients will be recruited. All the patients will receive biopsy genotype assay and Circulating Single-Molecule Amplification and Resequencing Technology (cSMART) liquid biopsy. those patients who carry EGFR activating mutation and other TKI targeted activating mutation will receive TKI treatment. During the TKI treatment, every patients will take liquid biopsy assay to monitor the mutation status. the study will be ended when all the patients had a progressive disease (PD) in their targeted lesion

Clinical Study Identifier: NCT02980536

Contact Investigators or Research Sites near you

Start Over

Hua Zhang, MS

Baogang Hospital
Baotou, China

Xiaohong Wang, MD

Baotou Cancer Hospital
Baotou, China

Fengyun Wang, MD

Northern Hospital Baotou
Baotou, China

Shubing Wang, MD

Baotou Centry Hospital
Baotou, China

Xiaoyu Shi, MD

Bayan Nur Hospital
Bayan Nur, China

Xiaoqiong Jia, MD

The Inner Mongolia Autonomous Region Cancer Hospital
Hohhot, China

Hui Li, MD

The Inner Mongolia Autonomous Region People's Hospital
Hohhot, China

Xiuhua Fu, MD

The First Affiliated Hospital of Inner Monglia Medical University
Hohhot, China

Qiong Qin, MD

Dalad Banner People's Hospital
Ordos, China

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.